Clinical trial • Phase II • Cardiology
ESKETAMINE HYDROCHLORIDE for Out-of-hospital cardiac arrest
Phase II trial of ESKETAMINE HYDROCHLORIDE for Out-of-hospital cardiac arrest.
Overview
- Trial Therapeutic Area
- Cardiology
- Trial Disease
- Out-of-hospital cardiac arrest
- Trial Stage
- Phase II
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 25-07-2024
- First CTIS Authorization Date
- 01-10-2024
Trial design
Randomised, propolipid (propofol) — emulsion for injection/infusion; max total dose 6 mg/kg (doseuom: mg/kg); route: intravenous bolus injection/iv infusion.-controlled Phase II trial across 2 sites in Denmark.
- Randomised
- Yes
- Comparator
- Propolipid (propofol) — EMULSION FOR INJECTION/INFUSION; max total dose 6 mg/kg (doseUom: mg/kg); route: INTRAVENOUS BOLUS INJECTION/IV INFUSION.
- Target Sample Size
- 282
- Trial Duration For Participant
- 180
Eligibility
Recruits 282 Vulnerable population selected. Subject information and informed consent forms are provided for subject, trial guardian, next of kin, and death next of kin, indicating consent/permission processes via trial guardian or next of kin for incapacitated participants..
- Pregnancy Exclusion
- Woman of childbearing capacity (female aged 18-40, decided by the treating physician if no information is available)
- Vulnerable Population
- Vulnerable population selected. Subject information and informed consent forms are provided for subject, trial guardian, next of kin, and death next of kin, indicating consent/permission processes via trial guardian or next of kin for incapacitated participants.
Inclusion criteria
- {"criterion_text":"- 1.\tAge ≥18 years (presumed if not known)\n- 2.\tOHCA of presumed cardiac cause. *\n- 3.\tPrimary shockable rhythm (ventricular fibrillation or pulseless ventricular tachycardia) **\n- 4.\tDecision to perform prehospital intubation after resuscitation (as decided by treating physician) or intubated during CPR with additional need for sedation.\n- 5.\tAdministration of study medicine injection before hospital arrival is considered feasible.\n- 6.\tROSC with MAP ≥40 mmHg *i.e. admission to Rigshospitalet or Odense University Hospital: national guidelines state that all OHCA patients with presumed cardiac arrest must be referred to the two main hospitals in the respective regions — Rigshospitalet for all OHCA cases in Region Zealand and the Capital Region, and Odense University Hospital for all OHCA cases in Region South. **If a defibrillator shock by an automated external defibrillator is delivered or advised before arrival of the EMS, it is considered a “primary shockable rhythm.”"}
Exclusion criteria
- {"criterion_text":"- 1.\tAdvanced life support TOR exclusion criteria fulfilled\n- 2.\tRefractory cardiac arrest transferred for extracorporeal membrane oxygenation\n- 3.\tWoman of childbearing capacity (female aged 18-40, decided by the treating physician if no information is available)\n- 4.\tKnown therapy limitation (known decision made of no resuscitation or intensive therapy)\n- 5.\tKnown allergy to ketamine or propofol\n- 6.\tSystolic blood pressure >190 mmHg\n- 7.\tKnown chronic disease making 180-day survival unlikely\n- 8.\tKnown pre-arrest mRS score of ≤5\n- 9.\tNursing home resident\n- 10.\tTemperature upon admission <30° C"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Neuron-specific enolase (NSE) measured 48 hours after OHCA","definition_or_measurement_approach":"NSE biomarker measured 48 hours after out-of-hospital cardiac arrest (measurement timepoint specified as 48 hours)."}
Secondary endpoints
- {"endpoint_text":"- Death from all causes at 180 days after cardiac arrest.\n- CPC- and mRS score at hospital discharge and 180-240 days after cardiac arrest.","definition_or_measurement_approach":"Death from all causes assessed at 180 days post-arrest. Cerebral Performance Category (CPC) and modified Rankin Scale (mRS) scores assessed at hospital discharge and at 180-240 days after cardiac arrest."}
Recruitment
- Planned Sample Size
- 282
- Recruitment Window Months
- 36
- Consent Approach
- Informed consent/permission materials exist for subjects, trial guardians, next of kin, and death next of kin (documents listed: subject ICF, trial guardian ICF, next of kin ICF, death next of kin ICF). As the population are adults after OHCA and many will be incapacitated on enrollment, consent appears to be handled via trial guardian/next of kin documents. Languages of consent documents are not specified in the available record.
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 282
Denmark
- Earliest CTIS Part Ii Submission Date
- 27-09-2024
- Latest Decision Or Authorization Date
- 01-10-2024
- Processing Time Days
- 4
- Number Of Sites
- 2
- Number Of Participants
- 282
Sites
- Site Name
- Rigshospitalet
- Department Name
- Department of Cardiology
- Principal Investigator Name
- Christian Hassager
- Principal Investigator Email
- christian.hassager@regionh.dk
- Contact Person Name
- Christian Hassager
- Contact Person Email
- christian.hassager@regionh.dk
- Site Name
- Odense University Hospital
- Department Name
- Department of Cardiothoracic Anesthesiology
- Principal Investigator Name
- Henrik Schmidt
- Principal Investigator Email
- henrik.schmidt@rsyd.dk
- Contact Person Name
- Henrik Schmidt
- Contact Person Email
- henrik.schmidt@rsyd.dk
Sponsor
Primary sponsor
- Full Name
- Rigshospitalet
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Third parties
- {"country":"Denmark","full_name":"Frederiksberg Hospital","duties_or_roles":"[{\"id\":593667,\"code\":\"1\"}]","organisation_type":"Hospital/Clinic/Other health care facility"}
Investigational products
- Investigational Product Name
- S-ketamin "Pfizer" injektionsvæske, opløsning
- Active Substance
- ESKETAMINE HYDROCHLORIDE
- Modality
- Small molecule
- Routes Of Administration
- INTRAVENOUS BOLUS INJECTION/IV INFUSION
- Route
- INTRAVENOUS BOLUS INJECTION/IV INFUSION
- Authorisation Status
- Authorised (marketing authorisation number 19569 in DK)
- Maximum Dose
- 4 mg/kg
- Investigational Product Name
- Propolipid
- Active Substance
- PROPOFOL
- Modality
- Small molecule
- Routes Of Administration
- INTRAVENOUS BOLUS INJECTION/IV INFUSION
- Route
- INTRAVENOUS BOLUS INJECTION/IV INFUSION
- Authorisation Status
- Authorised (marketing authorisation number 49586; MRP DE/H/0490/003 referenced)
- Maximum Dose
- 6 mg/kg
Related trials
Other published trials that may interest you.